This site is intended for healthcare professionals
Journals
  • Home
  • /
  • Journals
  • /
  • Breast Cancer
  • /
  • Ribociclib for post-menopausal women with HR+/HER2...
Journal

Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.

Read time: 1 mins
Published:6th Sep 2017
Author: Zangardi ML, Spring LM, Blouin GC, Bardia A.
Availability: Pay for access, or by subscription
Ref.:Expert Rev Clin Pharmacol. 2017.
DOI:10.1080/17512433.2017.1376653

Introduction: The introduction of CDK4/6 inhibitors, such as ribociclib, has changed the treatment landscape for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer. As first-line treatment of HR+/HER2- MBC, the addition of a CDK4/6 inhibitor to an aromatase inhibitor improves progression-free survival compared to an aromatase inhibitor alone.

Areas covered: In this drug profile, we review the current market for HR+/HER2- MBC, as well as the characteristics, mechanism, pharmacology, pharmacodynamics, pharmacokinetics, metabolism, clinical efficacy, toxicities, monitoring, and dosing modification of the CDK4/6 inhibitor ribociclib.

Expert commentary: CDK4/6 inhibitors, such as ribociclib, improve outcomes in post-menopausal women with HR+/HER2- MBC. The most common toxicity of ribociclib is neutropenia, which is generally not complicated and can be managed with dose modification and/or supportive care measures. Additional research will help better define the optimal clinical use of ribociclib.

 

Read abstract on library site

Access full article